*10:15JST media network—the National Cancer Research Center and the COVID-19 of the prevention and research collaboration agreement
Media net<2370>On December 3, the National Cancer Center and the new corona virus infection [COVID-19]to prevent SARS-CoV-2 antigen-pulsed autologous dendritic cell vaccine for the development of a joint research agreement signed and announced.
The new coronavirus infection global infection continued to expand,vaccine development is urgently needed. The world is being developed by a vaccine is generally 液性免疫 by SARS-CoV-2 for neutralizing antibody production of the virus to the cells of the infected defenses is aimed. Recent studies of these vaccines by SARS-CoV-2 for the antibody titer is maintained long-term might not suggest it, or a vaccine administered by the antibody titer is sufficiently elevated, if severe may induce also been concerned about.
Autologous dendritic cell vaccine, this vaccine, unlike dendritic cells in SARS-CoV-2 antigen-pulsed cell-mediated immunity by cytotoxic lymphocytes [CTL]induced in the body, the virus infected cell’s killing,the removal can expect. In addition, some of the CTLS or memory T cells by SARS-CoV-2 cells against the cytotoxic activity with the host in the memory for long-term preventive effect is expected. Autologous dendritic cell vaccine, the company is in the field of cancer treatment on its own development, and already in clinical use safety proven dendritic cell vaccine production technology to take advantage. In addition, the company through this research,new type of corona virus infection is not limited to the dendritic cell vaccine platform application, with a view to rapid vaccine development and society contribution to the goal. 《ST》